abstract

1 stories · following the connections

Business

Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody” in Conjunction with 2017 ASCO Annual Meeting

By Nasdaq OMXMay 19, 2017, 12:29 PM UTC